首頁
BioDelivery Sciences International, Inc.

7月 2026BioDelivery Sciences Int...的市場佔有率分析

健康 > 生物技術和製藥

域名bdsi.com

成立年份1997

僱員201 - 500

年度營收$100M - $200M

BioDelivery Sciences International, Inc.

BioDelivery Sciences International, Inc.（包含公司地區）

bdsi.com

查看更多網站流量與參與度資訊

BioDelivery Sciences International, Inc.截至 7月 2026 的總收入為 100M - 200M

BioDelivery Sciences International, Inc. 熱門網域產生的總收入

BioDelivery Sciences International, Inc. 熱門網域 3 年內的總收入

BioDelivery Sciences International, Inc. 熱門網域的總收入

bdsi.com100M - 200M

透過銷售情報查看更多內容

BioDelivery Sciences International, Inc.的熱門網域總造訪量

了解BioDelivery Sciences International, Inc.市場觸達率與潛在市場影響力。

過去 3 個月的訪問總量

無可顯示數據

BioDelivery Sciences International, Inc.的熱門網域平均造訪時長

分析BioDelivery Sciences International, Inc.參與度指標。

過去 3 個月平均造訪時長

無可顯示數據

BioDelivery Sciences International, Inc.的熱門網域平均頁面瀏覽量

了解BioDelivery Sciences International, Inc.如何保持使用者的參與度、培養其興趣，並鼓勵他們採取下一步。

過去 3 個月平均頁面瀏覽量

無可顯示數據

BioDelivery Sciences International, Inc.按網域劃分的熱門競爭對手

7月 2026的熱門類似網站，依相似度排名

google.com公司名Google僱員> 10001總部美國, 加利福尼亞, Mountain View年度營收> $1B訪問總量88.4B電腦電子與科技 > 搜尋引擎

使用的熱門技術BioDelivery Sciences International, Inc.

这些是BioDelivery Sciences International, Inc.顶级域名使用的行业网站技术

付款與貨幣 (8)

Cart Functionality

付費廣告 (6)

Google Adsense

小工具 (5)

Twemoji

轉換與分析 (4)

Google Analytics

更多技術

10

檢視所有

新聞與訊號來自BioDelivery Sciences International, Inc.

透過 Similarweb 銷售訊號提醒，每當目標受眾出現新的機會或威脅時，你就會收到每日更新的已識別購買訊號。

新聞BioDelivery Sciences International launched ELYXYB TM (celecoxib oral solution on Feb 24th '22.BioDelivery Sciences International Announces ELYXYB™ is Now Available in the U.S. for the Acute Treatment of Migraine RALEIGH, N.C., Feb. 24, 2022 (GLOBE NEWSWIRE) -- BioDelivery Sciences International, Inc. (NASDAQ: BDSI), a growing specialty pharmaceutical company dedicated to patients living with serious and complex chronic conditions, today announced the U.S. commercial launch and availability of ELYXYB TM (celecoxib oral solution), the first and only FDA-approved ready-to-use oral solution for the acute treatment of migraine with or without aura in adults.

新聞BioDelivery Sciences International hired John Golubieski as Chief Financial Officer on Oct 21st '21.BioDelivery Sciences International, Inc. (NASDAQ: BDSI), a rapidly growing commercial-stage specialty pharmaceutical company dedicated to patients living with chronic conditions, today announced the appointment of John Golubieski as Chief Financial Officer, effective November 4, 2021.

新聞BioDelivery Sciences International promotes Terry Coelho to Executive Vice President and Chief Financial Officer.BioDelivery Sciences International, Inc. (NASDAQ: BDSI), a rapidly growing specialty pharmaceutical company dedicated to patients living with chronic conditions, promoted its Chief Financial Officer, Terry Coelho, to Executive Vice President and Chief Financial Officer.